Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First in human trial assessing CLR 121225

Next Previous
Trial Profile

First in human trial assessing CLR 121225

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CLR 121225 (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; First in man

Most Recent Events

  • 26 Jun 2025 According to Cellectar Biosciences media release, Cellectar Biosciences and Nusano formed an supply agreement to support clinical trials of CLR 125 for triple negative breast cancer and CLR 225 for pancreatic cancer.
  • 10 Dec 2024 According to Cellectar Biosciences media release, company expects to file Investigational New Drug applications in the first half of 2025 for both CLR-121225 and CLR-121125, which will allow the initiation of Phase 1 clinical studies in solid tumor cancers.
  • 21 Nov 2024 According to Cellectar Biosciences media release, today announced the signing of a strategic Master Supply Agreement with Cellectar Biosciences under which Cellectar will acquire and integrate NorthStar's Ac-225 into Cellectar's proprietary Phospholipid Ethers (PLE) delivery platform to expand the platform's capability to produce a diverse range of radiotherapeutic molecules.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top